CND Life Sciences Closes Series A Equity Round
Summary
The companys strong growth has been fueled by its innovative Syn-One Test\xae that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinsons disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders.This is a defining time for the neurodegeneration field, said Richard J. Morello, CNDs chief executive officer. CND uses proven technology to help clinicians diagnose diseases like Parkinsons earlier and more precisely than ever before, while collaborating with biopharmaceutical companies to improve the chances for successful clinical trials for novel therapies. We are grateful for the significant support of our mission by many dedicated investors.CND launched its Syn-One Test in late 2019, which has been used by nearly 3,000 neurologists and other clinicians to aid in the diagnosis of synuclein-associated disorders like PD for more than 35,000 patients. Additionally, Syn-One Biomarker Technology, which leverages CNDs AI-assisted platform NerValence to quantify the amount of synuclein detected in cutaneous nerves, is being applied in multiple pharmaceutical clinical trials with the hope of measuring an investigational drugs effect on the pathological protein.Without accurate diagnosis and objective measures of disease progression and therapy response, treatment of the synuclein-related disorders will be hampered, said Christopher Gibbons, MD, chief scientific officer of CND. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinsons disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder.